Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 3/2014

01-03-2014 | Hospital Management of Diabetes (G Umpierrez, Section Editor)

Diabetes in Long-Term Care Facilities

Authors: Aaditya Singhal, Alissa R. Segal, Medha N. Munshi

Published in: Current Diabetes Reports | Issue 3/2014

Login to get access

Abstract

With the aging of the population and longer life expectancies, the prevalence of population with multiple chronic medical conditions has increased. Difficulty managing these conditions as people age (because of changes in physical, functional, or cognitive abilities and the complexity of many treatment regimens), has led to more individuals with multiple medical conditions admitted to the long-term care facilities. Older adults with diabetes residing in the long-term facilities represent the most vulnerable of this cohort. Studies that specifically target diabetes management in older population are lacking and those that target diabetes management in the long-term care facilities are even fewer. The lack of knowledge regarding the care of the elderly residing in long-term care with diabetes may lead to treatment failure and higher risk of hyperglycemia, as well as hypoglycemia. In aging populations, hypoglycemia has the potential for catastrophic consequences. To avoid this, the management of older population with diabetes and other medical comorbidities residing in long-term care facilities requires a more holistic approach compared with focusing on individual chronic disease goal achievement.
Literature
1.••
Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report. J Am Geriatr Soc. 2012;60:2342–56. This consensus paper delineates available evidence and consideration for issues that may influence treatment decisions in older adults with diabetes.CrossRef
2.••
Association AMD. Diabetes Management in the Long-Term Care Setting Clinical Practice Guideline. In: Columbia, MD: AMDA; 2008; revised 2010. These revised guidelines are the most up-to-date recommendations providing practical guidance for management of diabetes in long-term care settings.
3.
Munshi M. Managing the “geriatric syndrome” in patients with type 2 diabetes. Consult Pharm. 2008;23(Suppl B):12–6.PubMed
4.
Holt RM, Schwartz FL, Shubrook JH. Diabetes care in extended-care facilities: appropriate intensity of care? Diabetes Care. 2007;30:1454–8.PubMedCrossRef
5.•
National Diabetes Fact Sheet. General Information and National Estimates on Diabetes in United States. In: U.S. Department of Health and Human Services CDC (ed.) Atlanta, GA; 2011. This data sheet has the current prevalence of diabetes in various age groups and shows the burden of the disease and its complications in the U.S.
6.
Zhang X, Decker FH, Luo H, et al. Trends in the prevalence and comorbidities of diabetes mellitus in nursing home residents in the United States: 1995–2004. J Am Geriatr Soc. 2010;58:724–30.PubMedCrossRef
7.
Resnick HE, Heineman J, Stone R, Shorr RI. Diabetes in U.S. nursing homes, 2004. Diabetes Care. 2008;31:287–8.PubMedCrossRef
8.
Migdal A, Yarandi SS, Smiley D, Umpierrez GE. Update on diabetes in the elderly and in nursing home residents. J Am Med Dir Assoc. 2011;12:627–32 e2.PubMedCrossRef
9.••
American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46. This article shows the true economical and social impact of diabetes in U.S. It shows the high socioeconomic impact of aging population.CrossRef
10.
Meneilly GS. The pathophysiology of diabetes in the elderly. In: Medha N, Munshi LAL, editors. Geriatric diabetes. New York: Informa Healthcare; 2007. p. 29–36.CrossRef
11.
12.
Elahi D, Muller DC, Egan JM, et al. Glucose tolerance, glucose utilization and insulin secretion in ageing. Novartis Found Symp. 2002;242:222–42. discussion 242–6.PubMedCrossRef
13.
Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance—a mini-review. Gerontology. 2009;55:379–86.PubMedCrossRef
14.
Blaum C. Diabetes mellitus. In: Durso S, Sullivan GM, editors. Geriatric review syllabus: a core curriculum in geriatric medicine. 8th ed. New York: American Geriatric Society; 2013. p. 566–75.
15.
Meneilly GS. Diabetes. In: Evans J, Williams TF, Beattie BL, editors. Textbook of geriatric medicine. 2nd ed. Oxford: Oxford University Press; 2000. p. 210–7.
16.
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRef
17.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef
18.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRef
19.
Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–92.PubMedCentralPubMedCrossRef
20.
Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.PubMedCentralPubMedCrossRef
21.
Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care. 1997;20:135–41.PubMedCrossRef
22.
Newton CA, Adeel S, Sadeghi-Yarandi S, et al. Prevalence, quality of care, and complications in long term care residents with diabetes: a multi-center observational study. J Am Med Dir Assoc. 2013;14(11):842–6.PubMedCrossRef
23.
Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719–26.PubMedCentralPubMedCrossRef
24.•
Zhao W, Katzmarzyk PT, Horswell R, et al. Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care. 2013;36(10):3287–96. This prospective cohort study contributes to understanding of level of BP control in patients with coronary heart disease and diabetes. The study shows a "U" shaped associated between BP and risk of CHD suggesting that aggressive BP cotnrol is associated with increase risk of CHD in patients with diabetes.PubMedCrossRef
25.
Sinclair A, Morley JE, Rodriguez-Manas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology. and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc. 2012;13:497–502.PubMedCrossRef
26.•
Sinclair AJ, Paolisso G, Castro M, et al. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37 Suppl 3:S27–38. This positions statement delineates guidelines and opinons by an international panel of experts.PubMedCrossRef
27.
Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892–9.PubMedCrossRef
28.
Lee CG, Boyko EJ, Barrett-Connor E, et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011;34:2381–6.PubMedCentralPubMedCrossRef
29.
30.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.PubMedCrossRef
31.
Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007;30:3017–22.PubMedCrossRef
32.
Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013;8:419–30.PubMedCentralPubMedCrossRef
33.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
34.
American Geriatrics Society. Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.CrossRef
35.
van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–63.PubMedCrossRef
36.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–71.PubMedCrossRef
37.
38.
Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820–5.PubMedCrossRef
39.
Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012;184:E675–83.PubMedCentralPubMedCrossRef
40.
Bode B, Sinclair A, Harris S, Vijapurkar U, Mayer C, Fung A, et al. Efficacy and safety of canagliflozin in older subjects with type 2 diabetes. In: The 73rd scientific sessions of the American Diabetes Association. Chicago, IL: Diabetes. 2013; p. LB-76.
41.••
Munshi MN, Pandya N, Umpierrez GE, et al. Contributions of basal and prandial hyperglycemia to total hyperglycemia in older and younger adults with type 2 diabetes mellitus. J Am Geriatr Soc. 2013;61:535–41. This meta-analysis provides important information about differences in hyperglycemia patterns in old vs young patients. This information can be used to target hyperglycemia differently in older patients and avoid treatment induced hypoglycemia.PubMedCrossRef
42.
Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–47.PubMedCrossRef
43.
Karnieli E, Baeres FM, Dzida G, et al. Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE). Drugs Aging. 2013;30:167–75.PubMedCentralPubMedCrossRef
44.
Alissa R, Segal P, Munshi MN. Insulin therapy for older adults with diabetes. Geriatr Aging. 2008;11:357–62.
45.
Pandya N, Nathanson E. Managing diabetes in long-term care facilities: benefits of switching from human insulin to insulin analogs. J Am Med Dir Assoc. 2010;11:171–8.PubMedCrossRef
46.
American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care. 1998;21:296–309.CrossRef
Metadata
Title
Diabetes in Long-Term Care Facilities
Authors
Aaditya Singhal
Alissa R. Segal
Medha N. Munshi
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 3/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-013-0464-y

Other articles of this Issue 3/2014

Current Diabetes Reports 3/2014 Go to the issue

Health Care Delivery Systems in Diabetes (D Wexler, Section Editor)

Effectiveness of Diabetes Interventions in the Patient-Centered Medical Home

Health Care Delivery Systems in Diabetes (D Wexler, Section Editor)

Integrated Community-Healthcare Diabetes Interventions to Reduce Disparities

Health Care Delivery Systems in Diabetes (D Wexler, Section Editor)

Quality Indicators and Performance Measures in Diabetes Care

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

How Do We Know if the Brain Is Wired for Type 2 Diabetes?

Hospital Management of Diabetes (G Umpierrez, Section Editor)

The Use of Non-Insulin Anti-Diabetic Agents to Improve Glycemia Without Hypoglycemia in the Hospital Setting: Focus on Incretins

Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

The Potential of Cell-based Therapy for Diabetes and Diabetes-related Vascular Complications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits